1. Home
  2. CTRM vs CLGN Comparison

CTRM vs CLGN Comparison

Compare CTRM & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castor Maritime Inc.

CTRM

Castor Maritime Inc.

N/A

Current Price

$2.20

Market Cap

21.2M

ML Signal

N/A

Logo CollPlant Biotechnologies Ltd

CLGN

CollPlant Biotechnologies Ltd

N/A

Current Price

$0.63

Market Cap

18.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CTRM
CLGN
Founded
2016
2004
Country
Cyprus
Israel
Employees
N/A
N/A
Industry
Marine Transportation
Industrial Specialties
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.2M
18.4M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
CTRM
CLGN
Price
$2.20
$0.63
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$11.00
AVG Volume (30 Days)
55.1K
99.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1,596.12
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.84
$0.50
52 Week High
$2.67
$4.98

Technical Indicators

Market Signals
Indicator
CTRM
CLGN
Relative Strength Index (RSI) 51.61 34.59
Support Level $2.04 $0.50
Resistance Level $2.43 $1.60
Average True Range (ATR) 0.10 0.08
MACD -0.01 0.04
Stochastic Oscillator 34.48 63.40

Price Performance

Historical Comparison
CTRM
CLGN

About CTRM Castor Maritime Inc.

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

Share on Social Networks: